Presenters, including Nobel Laureate in
Medicine, to discuss innovative treatments for
neurodegeneration
Company to feature lead therapeutic's
statistically significant benefits, p < 0.007, for severe
Alzheimer's disease (AD) patients
NEW
YORK, Dec. 6, 2023 /PRNewswire/ -- Synaptogenix,
Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging
biopharmaceutical company developing therapeutics for
neurodegenerative disorders, today announced that its President and
Chief Scientific Officer, Daniel
Alkon, M.D., will join more than 30 leading neuroscientists
and academics as a speaker at IABS Forum-2023, "New Concepts for
the Treatment of Neurodegenerative Disorders." The distinguished
scientific forum, to be held on December
7-8, 2023 in Irvine, CA, is
co-sponsored by the University of Southern
California School of Pharmacy and the International
Association of Biomedical Sciences (IABS).
The forum's keynote address, entitled "Towards a Cell Biology of
Alzheimer's Disease," will be delivered by Dr. Thomas Südhof, Nobel
Laureate in Physiology or Medicine 2013. Dr. Südhof is known
for his groundbreaking research on the mechanisms underlying
synaptic transmission, which plays a vital role in learning,
memory, and various neurological processes.
AD is also the topic of Dr. Alkon's presentation. He will speak
about the latest clinical results for Bryostatin-1, which, as
previously disclosed, met the secondary efficacy endpoints in the
Phase 2 trial with statistical significance. In the Phase 2 trial,
no significant cognitive decline was observed throughout the
10-month study, with Bryostatin-1 demonstrating safe, significant,
and persistent benefits at least 16 weeks beyond the final dosing.
A research article detailing the results was published earlier this
year in the Journal of Alzheimer's Disease.
"I am honored to accept the invitation to speak at IABS
Forum-2023, in the company of many of the world's greatest minds in
neuroscience," said Dr. Alkon. "Renowned institutions, publishers,
and symposiums continue to recognize the benefits of our novel
therapy, developed to restore synaptic loss, and its potential for
advanced stage Alzheimer's patients."
About Synaptogenix
Synaptogenix is a clinical-stage biopharmaceutical company that
has historically worked to develop novel therapies
for neurodegenerative diseases. Synaptogenix has conducted
clinical and preclinical studies of its lead therapeutic candidate,
Bryostatin-1, in Alzheimer's disease. Preclinical studies have also
demonstrated Bryostatin's regenerative mechanisms of action for the
rare disease Fragile X syndrome, and for other neurodegenerative
disorders such as multiple sclerosis, stroke, and traumatic brain
injury. The U.S. Food and Drug Administration has granted Orphan
Drug Designation to Synaptogenix for Bryostatin-1 as a treatment
for Fragile X syndrome. Bryostatin-1 has already undergone testing
in more than 1,500 people in cancer studies, thus creating a large
safety data base that will further inform clinical trial designs.
Additional information about Synaptogenix, Inc. may be found on its
website: www.synaptogen.com
Forward-Looking Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements. Such forward-looking statements are subject to risks
and uncertainties and other influences, many of which the Company
has no control over. There can be no assurance that the clinical
program for Bryostatin-1 will be successful in demonstrating safety
and/or efficacy, that the Company will not encounter problems or
delays in clinical development, or that Bryostatin-1 will ever
receive regulatory approval or be successfully commercialized.
Actual results and the timing of certain events and circumstances
may differ materially from those described by the forward-looking
statements as a result of these risks and uncertainties. Additional
factors that may influence or cause actual results to differ
materially from expected or desired results may include, without
limitation, the Company's inability to obtain adequate financing,
the significant length of time associated with drug development and
related insufficient cash flows and resulting illiquidity, the
Company's patent portfolio, the Company's inability to expand its
business, significant government regulation of pharmaceuticals and
the healthcare industry, lack of product diversification,
availability of the Company's raw materials, existing or increased
competition, stock volatility and illiquidity, and the Company's
failure to implement its business plans or strategies. These and
other factors are identified and described in more detail in the
Company's filings with the Securities and Exchange Commission. The
Company does not undertake to update these forward-looking
statements.
Contact
800-811-5591
ir@synaptogen.com
View original
content:https://www.prnewswire.com/news-releases/synaptogenix-joins-leading-neuroscientists-and-academics-as-speaker-at-usc-sponsored-forum-on-age-related-diseases-including-alzheimers-302007192.html
SOURCE Synaptogenix, Inc.
